Brighton Park Capital Opens London Office
Brighton Park has been an active investor in the EMEA region for years, partnering with exceptional entrepreneurs and breakthrough companies. The establishment of the London office deepens the firm's presence in Europe—strengthening local relationships, unlocking new investment opportunities, and enhancing its ability to support companies as they launch and scale strategies in the UK and EU, and expand into the U.S.
'The opening of our London office marks a significant milestone in our mission to back the next generation of category-defining software companies,' said Mark Dzialga, Managing Partner at Brighton Park Capital. 'Europe is home to a growing wave of founder-led businesses building globally relevant, AI-powered platforms with deep technical differentiation. We're excited to bring our capital, network, and company-building expertise to support these exceptional entrepreneurs across the continent.'
Mr. Dzialga continued, 'We have had a longstanding relationship with Tom, and he is the ideal person to spearhead this effort. Tom has demonstrated outstanding company-building skills and has been successful in investing in most of the major markets in Europe. Tom also has a deep network of relationships in the growth equity ecosystem.'
Mr. Hussey joins Brighton Park Capital following 12 years at General Atlantic, where he focused on technology investments and co-chaired the EMEA Investment Committee. He played a key role in more than 20 investments and exits across EMEA, including Adevinta, Argus Media, Epsilon Net, Hemnet, and Odoo. Earlier in his career, Mr. Hussey was with The Boston Consulting Group.
'Europe is producing a new generation of visionary founders who are building AI-native software and healthcare technology companies with global ambition,' said Mr. Hussey. 'I'm excited to lead our efforts from London—helping these innovative teams scale their businesses across Europe, expand into the U.S., and navigate the opportunities and challenges of international growth.'
About Brighton Park Capital
Brighton Park Capital is a New York-based investment firm focused on entrepreneur-led, growth-stage software, healthcare and tech-enabled services companies. The firm invests in companies that provide highly innovative solutions in partnership with great management teams. Brighton Park brings purpose-built, value-add capabilities that match the unique requirements of each of its companies. For more information about Brighton Park Capital, please visit www.bpc.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) ('Protara' or the 'Company'), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees. The Compensation Committee of Protara's Board of Directors approved an aggregate of 14,800 stock option awards and 7,400 RSU awards to two new employees from the Inducement Plan, as inducements material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on August 1, 2025 and have an exercise price of $3.06 per share, Protara's closing trading price on the grant date. Such RSU awards will have a grant date of October 1, 2025. All option awards vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and 1/36th of the underlying shares vesting monthly thereafter over 36 months. All RSU awards vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date. The vesting of all option and RSU awards is subject to the employee's continued service with the company through the applicable vesting dates. About Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit Company Contact: Justine O'Malley Protara 646-817-2836 Source: Protara TherapeuticsSign in to access your portfolio
Yahoo
an hour ago
- Yahoo
ETF Issuers Line Up to Capitalize on Figma's Red Hot IPO
The stock price of tech start-up Figma Inc. (FIG) more than tripled during its debut on the New York Stock Exchange—and exchange-traded fund (ETF) issuers want in on the action. Themes ETF Trust is seeking approval from the Securities and Exchange Commission (SEC) to launch the Leverage Shares 2X Long FIG Daily ETF, according to a filing Thursday. ProShares and REX Shares are also looking to introduce leveraged ETFs linked to Figma, which had its initial public offering (IPO) Thursday. Leveraged Figma ETFs The Leverage Shares 2X Long FIG Daily ETF seeks to magnify the daily performance of Figma's stock by 200%, according to the filing, which didn't disclose management fees. The ProShares Ultra FIG—with no ticker or expense ratio included in the preliminary prospectus—also seeks daily investment results that correspond to two times FIG's daily performance. Eric Balchunas, senior ETF analyst at Bloomberg, also shared on X that Rex Shares filed for a similar fund: the T-Rex 2x Long FIG Daily Target ETF. What Is Figma? Figma is a San Francisco-based company that provides a design platform. The start-up had previously struck a deal to be bought for $20 billion by the software company Adobe Inc. (ADBE), but that plan was abandoned due to antitrust concerns from regulators in the U.S. and Europe. The Appeal of IPO-Linked ETFs It's no surprise that these issues are looking to capitalize on Figma's IPO: The stock debuted at $33 per share and closed its first day on the market at $115.50 per share, marking the biggest pop for a $500 million-plus IPO, and the first time a deal that size has ever tripled on day one, Matt Kennedy, senior strategist at Renaissance Capital told Invest in Gold American Hartford Gold: #1 Precious Metals Dealer in the Nation Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase Thor Metals Group: Best Overall Gold IRA 'I think the appeal is that recent tech IPOs tend to be very volatile, which means the stock has the potential for a 5% or even 10% gain in one day, and so a 2x leveraged daily ETF allows traders to really ride those quick run-ups,' Kennedy said. 'It's a way of making your bet go further, if you're actively trading the stock during the day. In June, several fund providers, including REX Shares, sought to launch ETFs linked to the IPO of peer-to-peer payments company Circle. At the time, Daniel Sotiroff, senior manager research analyst for Morningstar Research, said that leveraged ETFs tend to succumb to volatility drag and perform poorly over the long | © Copyright 2025 All rights reserved Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Guggenheim Investments Announces August 2025 Closed-End Fund Distributions
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Guggenheim Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution schedule for each closed-end fund (collectively, the 'Funds' and each, a 'Fund'). The following dates apply to the distributions: Record Date August 15, 2025 Ex-Dividend Date August 15, 2025 Payable Date August 29, 2025 Distribution Schedule NYSE Ticker Closed-End Fund Name Distribution Per Share Change from Previous Distribution Frequency AVK Advent Convertible and Income Fund $0.1172† Monthly GBAB Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust $0.12573† Monthly GOF Guggenheim Strategic Opportunities Fund $0.1821† Monthly GUG Guggenheim Active Allocation Fund $0.11875† Monthly † A portion of this distribution is estimated to be a return of capital rather than income. Final determination of the character of distributions will be made at year-end. The Section 19(a) notice referenced below provides more information and can be found at You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's Distribution Policy. Past performance is not indicative of future performance. As of this announcement, the sources of each fund distribution are estimates. Distributions may be paid from sources of income other than ordinary income, such as short-term capital gains, long-term capital gains or return of capital. Unless otherwise noted, the distributions above are not anticipated to include a return of capital. If a distribution consists of something other than ordinary income, a Section 19(a) notice detailing the anticipated source(s) of the distribution will be made available. The Section 19(a) notice will be posted to a Fund's website and to the Depository Trust & Clearing Corporation so that brokers can distribute such notices to Shareholders of the Fund. Section 19(a) notices are provided for informational purposes only and not for tax reporting purposes. The final determination of the source and tax characteristics of all distributions will be made after the end of the year. This information is not legal or tax advice. Consult a professional regarding your specific legal or tax matters. About Guggenheim Investments Guggenheim Investments is the global asset management and investment advisory division of Guggenheim Partners, LLC ('Guggenheim'), with more than $253 billion* in assets under management across fixed income, equity, and alternative strategies. We focus on the return and risk needs of insurance companies, corporate and public pension funds, sovereign wealth funds, endowments and foundations, consultants, wealth managers, and high-net-worth investors. Our 220+ investment professionals perform rigorous research to understand market trends and identify undervalued opportunities in areas that are often complex and underfollowed. This approach to investment management has enabled us to deliver innovative strategies providing diversification opportunities and attractive long-term results. Guggenheim Investments includes Guggenheim Funds Investment Advisors, LLC ('GFIA'), Guggenheim Partners Investment Management, LLC ('GPIM') and Guggenheim Funds Distributors, LLC ('GFD'). GFIA serves as Investment Adviser for GBAB, GOF and GUG. GPIM serves as Investment Sub-Adviser for GBAB, GOF and GUG. GFD serves as servicing agent for AVK. The Investment Adviser for AVK is Advent Capital Management, LLC and is not affiliated with Guggenheim. *Assets under management are as of 6.30.2025 and include leverage of $14.8bn. Guggenheim Investments represents the following affiliated investment management businesses of Guggenheim Partners, LLC: Guggenheim Partners Investment Management, LLC, Security Investors, LLC, Guggenheim Funds Distributors, LLC, Guggenheim Funds Investment Advisors, LLC, Guggenheim Corporate Funding, LLC, Guggenheim Wealth Solutions, LLC, Guggenheim Partners Europe Limited, Guggenheim Partners Japan Limited, GS GAMMA Advisors, LLC, and Guggenheim Private Investments, LLC. This information does not represent an offer to sell securities of the Funds and it is not soliciting an offer to buy securities of the Funds. There can be no assurance that the Funds will achieve their investment objectives. Investments in the Funds involve operating expenses and fees. The net asset value of the Funds will fluctuate with the value of the underlying securities. It is important to note that closed-end funds trade on their market value, not net asset value, and closed-end funds often trade at a discount to their net asset value. Past performance is not indicative of future performance. An investment in closed-end funds is subject to investment risk, including the possible loss of the entire amount that you invest. Some general risks and considerations associated with investing in a closed-end fund may include: Investment and Market Risk; Lower Grade Securities Risk; Equity Securities Risk; Foreign Securities Risk; Interest Rate Risk; Illiquidity Risk; Derivative Risk; Management Risk; Anti-Takeover Provisions; Market Disruption Risk and Leverage Risk. See for a detailed discussion of Fund-specific risks. Investors should consider the investment objectives and policies, risk considerations, charges and expenses of any investment before they invest. For this and more information, visit or contact a securities representative or Guggenheim Funds Distributors, LLC 227 West Monroe Street, Chicago, IL 60606, 800-345-7999. Analyst InquiriesWilliam T. Korvercefs@ Not FDIC-Insured | Not Bank-Guaranteed | May Lose ValueMember FINRA/SIPC (08/25) 65663
